
Trump's Risk With Looming European Union Trade War: Maybe Your Health
The European Union dominates a wide range of U.S. imports of medicines for treating diabetes, high blood pressure, depression and cancers as well as many of the chemical compounds that are then used to produce some of these same drugs and others domestically.
That's why, with President Trump's threatened 30% tariffs on the 27-nation European Union set to go into effect on Aug. 1, the stakes are more consequential to Americans than with trade wars he initiated with countries that provide cell phones, sweaters, toys or even motor vehicle parts.
Increased costs for critical medicines would hit the nation's poorest and uninsured the hardest, of course.
The European Union is sending some signals that it does not intend to back down. The tariff fight with the European Union is unique in that Trump tends to prefer bilateral negotiations; the European Union is composed of 27 countries.
Trump has twice delayed imposing most of the tariffs he initially announced on April 2 against the world, including more than 100 nations with which the United States has a trade surplus. The 10% baseline tariffs are in effect as well as some other industry-specific tariffs.
In taking on China, Canada, Mexico and the European Union, Trump is focusing on some of the largest U.S. trade deficits – but at the same time focusing on some of the United States' largest export markets, damaging a key metric in the process.
Overall, the European Union is accounting for 20.22% of all U.S. imports and 18.57% of all U.S. exports through May, the latest data available from the U.S. Census Bureau.
To see what imports would be most detrimental to the United States should the 30% tariffs actually go into effect next Friday, I focused on the categories of imports where the European Union has the greatest market share globally.
I focused on the top 50, which account for 73.29% of all its imports through May rather than all 1,200-plus. (For those familiar with the harmonized system, I am working at the four-digit level.)
What I found was that six of the 10 with the largest global market share were related to healthcare, ranging from 62.36% for one to 99.22% to another.
While medicines that are critical to Americans' health, and sometimes their lives, are in the bull's eye of American health, so too are U.S. exports for Europeans' health and well-being.
Six of the top 10 U.S. exports, calculated as in the manner described for imports above, are also related to healthcare. In fact, three of the six are the same for both exports and imports. On the export list, the European Union percentage of these six U.S. exports ranges from 46.78% to 98.86%.
Ireland dominates U.S. imports from the world of the category that includes insulin, hormones and ... More steroids.
Looking first at the U.S. imports, 99.22% of $42.95 billion in U.S. shipments in the insulin, hormone and steroid category (HS code 2937) are from the European Union, with 98.48% coming from Ireland. It is the top import from the European Union this year.
The same category is a top U.S. export to the European Union, accounting for 53.85% of $4.94 billion in U.S. exports to the world, ranking fourth overall.
The category that includes U.S. imports of plasma, vaccines and other blood "fractions" experienced ... More its best May ever. topping $10 billion for the first time.
In the import category of plasma, vaccines and other blood 'fractions,' 84.56% of the $54.29 billion total is entering from the European Union. Ireland and Germany are accounting for 47.57% of all U.S. imports in this category (HS code 3002) while the Netherlands, Belgium, France, Switzerland and Italy account for another 28.07%. It is the second most important import from the European Union this year.
On the export side, the United States sends 53.85% of the $22.97 billion in shipments to the world to the European Union. It is the United States' fourth-ranked export to the European Union.
The third category (HS code 3003) that appears on both top 10 lists is for pharmaceuticals that are not in an individual dose form, such as pills.
On the U.S. import side, the European Union accounts for 76.05% of the $1.33 billion total through May; on the U.S. export side, the European Union accounts for 85.03% of the $541.75 million total.
On the import side, there are two categories of heterocyclic compounds, commonly used in the production of medicines. With one (HS code 2934), the European Union accounts for 84.56% of all U.S. imports and the other (HS code 2935), 62.36%. The value of the first is $4.48 billion, with the second at $2.61 billion.
The sixth and final import category where the European Union has the greatest market share is a category which, is something of a grab bag of chemical contraceptives, contrast agents administered during X-rays and other tests, and so-called sterile surgical catgut, which is used for internal stitches. In the case of the European Union, 74.37% of the $2.42 billion global total, $1.1 billion is chemical contraceptives.
Two of the four categories among the top 10 on the import side that do not fall under the broad umbrella of the healthcare industry are, however, well known U.S. imports from Europe, wine and perfume.
The European Union is responsible for 79.77% of the $2.97 billion in wine imports into the United States through May and 80.78% of $2.15 billion in perfumes.
While these are the U.S. import categories that the European Union dominates by global market share, they are not the largest by value.
Among those not mentioned above for market share that are among the top 10 by value from the European Union:
Switching over to the U.S. export side, these three were among those with the largest market share not previously mentioned:
Four top 10 exports by value, rather than market share, headed to the European Union are worth mentioning:
The range of U.S. imports sent from the European Union and U.S. exports to the European Union is wide-ranging but when looking just as where the E.U. is either a dominant importer into the United States or buyer of U.S. exports, healthcare holds a dominant presence, making Trump's threatened 30% tariffs on imports from the 27-nation bloc set to go into effect on Aug. 1, particularly risky for Americans and Europeans alike.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Top analyst sends message on pending ugly earnings miss (plus one big beat)
Top analyst sends message on pending ugly earnings miss (plus one big beat) originally appeared on TheStreet. Wall Street always punishes bad performers when quarterly results come around, but it seems as though earnings misses are really bringing out the worst in investors this time around. Just last week, the market action reinforced the idea that 'good is not enough,' dropping Netflix by 5% last week despite the company raising its full-year guidance and beating its top and bottom lines. Likewise, big banks like Bank of America and JPMorgan suffered through muted gains when solid earnings and positive consumer news couldn't overcome the disappointment of not delivering even more. 💵💰 💵💰 There's a growing disconnect between the quality of performance a company delivers and Wall Street's reaction to whether those numbers were enough. With the market back around record-high levels, strong results alone may not justify current levels. The trend is not unexpected. Before earnings season heated up, Annex Wealth Management Chief Economist Brian Jacobsen noted in one of his regular 'Market Musing' posts that valuation should give investors pause right now. 'Valuations are poor timing tools, but they do help gauge upside and downside risks,' Jacobsen wrote. 'Considering where valuations are, as earnings season begins, it's reasonable to expect that earnings misses could have a bigger market impact than positive surprises.' Nearly 40% of S&P 500 companies are overstating earnings With the stepped-up action around earnings season, the analysts at New Constructs dusted off a previously popular feature, looking at the companies that are most likely to miss earnings, as well as those that are poised for a big earnings Constructs' methodology brings together discounted cash-flow analysis and forensic accounting, working backwards from most analysts by digging into a company's documents and the footnotes level and working up, rather than starting at the top-line and conducting the analysis only at a skin-deep level. As a result, New Constructs finds where the headline numbers mask a misleading situation. If that deception works in the favor of the investor, a stock is 'attractive,' but if the numbers could mislead the investor into trouble, the stock is 'dangerous.' The firm's stock-picking routinely has been rated by SumZero at or near the top of multiple investment categories; SumZero is a buy-side community in which more than 15,000 professional portfolio managers compete for rankings. As Company President David Trainer noted, seeing that a company is poised for a beat or a miss doesn't mean it will happen immediately or even the next time results are posted. He said, however, that without significant changes, the numbers make an earnings surprise nearly unavoidable. Moreover, as New Constructs starts looking for the earnings surprises, Trainer said in an interview on the Money Life with Chuck Jaffe podcast that 'Right now in the S&P, about 39% of companies are overstating their earnings by an average of around 14%.' Trainer noted that earnings tend to be overstated more frequently when the market is rallying. One casino stock has numbers to bet against In the 'Danger Zone' segment on the July 7 edition of Money Life, Trainer singled out Caesars Entertainment (CZR) as having 'misleading street earnings' caused by 'significant, unusual income' bloating its reported income levels. Trainer said Caesars – which gets an 'unattractive' rating from New Constructs in addition to being on the firm's most-likely-to-miss list – combines high valuations with slim profit Constructs research showed estimated Street earnings per share for the second quarter at 19 cents, but noted that estimated core earnings per share for Caesars were 10 cents, meaning the Street estimate is inflated by 46%. 'For equity investors, we're seeing a lot of a lot of risk here because you've got something like $26 billion in debt on a market cap of around $6 billion, with profits that are pretty razor thin,' Trainer said. 'So it doesn't take much to wipe out the equity holders.' Trainer said that New Constructs pegs the 'no-growth value' of Caesars at -$51 per share (yes, that's negative 51 bucks per share). 'This is one unattractive, dangerous stock,' Trainer said. 'They're pumping up the earnings, and you take away those fake earnings and you've got a business that could be on life support with an earnings miss.' On the flip side, more than half of the S&P 500 is understating earnings In a follow-up Danger Zone interview on the July 13 episode of Money Life, Trainer looked at the other side of the coin, noting that more than half of the companies in the S&P 500 actually have understated Street earnings projections, with 30% of the S&P 500 earnings understated by more than 10%. FactSet reported July 18 that analysts estimated earnings growth for S&P 500 companies had risen to 5.6% from an initial level of just under 5%, thanks to more companies reporting stronger-than-expected results. The question is whether the earnings surprises will be enough to placate Wall Street. Trainer made a pick of one company he thinks will make market sharpies happy, in Halliburton Co. () , where one-time and unusual expenses are dampening perception of the numbers. 'These are things [the company has] got to do once,' Trainer explained, 'so they're not really part of the ongoing profitability of the business. When these things go away, earnings will pop back up.' With that, Trainer said he would expect the company to be trading much closer to its economic book value of 'about 40 bucks a share,' a level that would nearly double the stock from its current pricing. He noted that Halliburton's valuation could be held down due to uncertainty over energy prices and to headline risks in the energy sector, 'but there's no reason a strong beat, a really strong beat here wouldn't cause the stock to spike up. There's clearly a lot of room for the stock to go up….You're still looking at a business that looks very much undervalued to us.' Top analyst sends message on pending ugly earnings miss (plus one big beat) first appeared on TheStreet on Jul 23, 2025 This story was originally reported by TheStreet on Jul 23, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
ezPOD Launches Open Beta Program to Transform Construction Material Delivery Documentation
Sheridan, Wyoming--(Newsfile Corp. - July 23, 2025) - ezPOD has announced the launch of its open beta program, offering construction industry professionals complimentary access to one of the first modern proof of delivery documentation platforms designed specifically for material providers, contractors, and drivers. ezPOD - Proof of Delivery Experts To view an enhanced version of this graphic, please visit: The limited-time beta program provides unlimited access to all platform features, including digital POD creation, photo uploads, GPS tracking, delivery timestamps, and permanent PDF documentation for construction material deliveries. "There are two goals for the open beta," said Ken Trent, Founder and CEO of ezPOD. "The first is to spread awareness and begin to refine our core audience and target customers. The second is to continue to refine the product, eliminate lingering bugs, and ensure a smooth and delightful customer experience when we finally do start charging for our service." The platform addresses a critical gap in the construction industry where no modern proof of delivery systems exist for large-scale material deliveries such as pallets of drywall, complete lumber packages, brick, stone, and framing hardware. Solving Real Industry Problems Trent's inspiration for ezPOD came from his experience at one of the nation's largest construction finance companies, where he witnessed contentious delivery disputes that could have been easily resolved with proper documentation. "We had a couple of very contentious disputes over material deliveries with customers," Trent explained. "If we had this product at that time, it would have immediately resolved the delivery dispute and helped all parties quickly move beyond the dispute and toward productive business operations." In one specific case, a contractor claimed they never received delivered materials. The material provider's paper proof of delivery documents were compromised by coffee stains that made materials and addresses illegible, while another document incorrectly listed the lumber yard as the destination rather than the origin address. "ezPOD would have solved this with GPS coordinates and timestamp of the delivery and photos taken," Trent noted. Comprehensive Digital Solution The ezPOD platform offers real-time material tracking, instant delivery notifications, precise GPS coordinates, photographic evidence, and automated PDF generation for each delivery transaction. All documentation is permanently stored and accessible via download or API integration. Unlike traditional paper-based systems prone to damage, loss, and human error, ezPOD creates tamper-proof digital records that provide accountability and transparency throughout the material delivery process. The platform targets three primary user categories: material providers who need reliable delivery documentation, contractors requiring proof of receipt, and drivers who must verify successful deliveries. Strategic Beta Launch The company's decision to offer all features complimentary during the beta period reflects a strategic approach to market entry and product refinement. By providing unrestricted access, ezPOD aims to build its user base across the construction supply chain while gathering operational data before transitioning to a paid model. Founded in March 2025, ezPOD represents Trent's extensive background in eCommerce and technology. The company's mission focuses on providing the best proof of delivery documentation for the construction industry while making the process simple, accessible, and modern. About ezPOD ezPOD is headquartered in Sheridan, Wyoming, and operates in the shipping services sector for residential and commercial construction. The company provides modern proof of delivery documentation solutions designed specifically for construction material deliveries, offering features including real-time tracking, GPS coordinates, photographic evidence, and permanent PDF documentation. For more information about the ezPOD open beta program, visit or contact Ken Trent directly. Contact Information: press@ To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
3 minutes ago
- Yahoo
Hilton's upbeat Q2 earnings: Why this analyst is still Neutral
Hilton (HLT) posted higher profit and revenue in the second quarter and raised its full-year outlook, but softer net income guidance and weaker occupancy are dragging on investor sentiment. Chad Beynon, Macquarie Group gaming, lodging & theatres analyst, joins Market Catalysts to explain why Hilton's upscale mix is a key factor behind his Neutral rating on the stock. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. Let's continue this travel conversation because Hilton is posting higher profit and revenue in the second quarter. It also raised its earnings outlook for the year. Still, the hotel operator's revenue per available room fell half a percent due to occupancy decline. Joining me now, Chad Beynon, Macquarie Group, Gaming, lodging, and theaters analyst. It's good to see you. So, um, as we are looking at, uh, these numbers, it looks like the company did trim its net income forecast a little bit. Um, although some of its metrics look good, what's your read on the quarter? Yeah, sure. Julie, thanks for having me. Uh, second quarter came in slightly better than expected. I think some of that was timing around termination fees and just kind of how, um, the holidays impacted some leisure versus, uh, business travel. Um, their third quarter guidance came in a little below expectations and where consensus was. So positive on Q2, negative on Q3, and then for the year, they kind of, uh, stood pat in terms of how they were thinking about the year. I would say the tone was slightly more positive, particularly, um, calling for more of a business travel recovery, uh, in the back half of the year. And then as it relates to the leisure traveler, as your last guest talked about, um, I think things are fine. I think consumers continue to prioritize experiences and we saw that, uh, this summer, uh, effects could be a slight positive because, uh, going to Europe or leaving the country is a little bit more expensive this year. Um, so as we've seen, uh, you know, people might stay closer home and vacation, uh, with drive to or shorter haul flights. Well, and I was talking earlier too about what we heard from the airlines, which seemed to be that sort of full service premium customers were holding up better. Are we seeing that play out in the lodging world as well? Absolutely. Uh, when we analyze the chain scale, uh, trends, um, revenue and occupancy in the United States, um, those higher-end full-service brands continue to outperform. I think that's been the case for almost a year now. So it certainly calls the question what's going on with that lower-end economy chain scale focused, uh, uh, brand or portfolio. Uh, so we continue to like those that lean a little bit more upscale, as we know the consumer is kind of fickle here. Um, you know, people are enjoying experiences. But the last two or three years, I think people extended their budgets in every, uh, age bracket. So the, uh, you know, people in that luxurious, uh, level were spending a little bit more. But also people in kind of the lower chain scales were, were spending more. So that's kind of what we're keeping an eye on. And our ratings kind of reflect a view towards some of the higher-end, uh, brands. Well, I was going to ask, I know you got a neutral rating, right? On Hilton? Um, is that why? Because they, you know, just because of their sort of hotel mix and who who their who their audience is? Yeah, I'd say fundamentally, I think net unit growth has probably been better than expected, uh, during the past couple years. The Rev par, uh, which is a key focus for analysts, um, has been roughly in line. I think one of the reasons why lodging stocks outperformed in 23 and 24, uh, compared to, uh, the S&P, it's really the business model, right? The franchisor business model continues, um, to receive praise from investors. And it was about a 10% outperformance for the group in 23 and in 24. So we're looking at these stocks trading, you know, around 30 times earnings, which is where we see high growth stocks, uh, in the market trading. So they're clearly in that category. And that's kind of been why we've maintained our neutral rating. It's certainly above historical trading levels and we are waiting for a little bit of a broader recovery, uh, to become more constructive on Hilton. Related Videos US equities lead 2025 ETF flows: A closer look at global trends Hasbro Q2 beat, MARA to raise $850M, Otis issues weak guidance GE Vernova, Thermo Fisher, Enphase Energy: Trending Tickers Japanese auto stocks are surging on Trump's tariff deal Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data